Anzeige
Mehr »
Freitag, 05.09.2025 - Börsentäglich über 12.000 News
SuperBuzz x Prymatica: Ein Vertriebsdeal, der KI-Hype in B2B-Umsätze verwandeln könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A414BN | ISIN: US47010C8881 | Ticker-Symbol: 1JA0
NASDAQ
04.09.25 | 16:16
1,640 US-Dollar
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
JAGUAR HEALTH INC Chart 1 Jahr
5-Tage-Chart
JAGUAR HEALTH INC 5-Tage-Chart

Aktuelle News zur JAGUAR HEALTH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.08.Jaguar Health, Inc.: Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs220Canalevia® (crofelemer delayed-release tablets), under the name Canalevia®-CA1, is conditionally approved by the FDA for treatment of CID in dogsCompany strategy: In discussions with multiple potential...
► Artikel lesen
20.08.Jaguar Health gibt strategische Einblicke in die Medikamentenentwicklung3
19.08.Jaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders739Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to registerAs announced, initial proof-of-concept results from the ongoing...
► Artikel lesen
19.08.Jaguar Health to meet with FDA on crofelemer for rare pediatric disease4
19.08.Jaguar Health, Inc.: Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease104As announced, initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating MVID...
► Artikel lesen
14.08.Jaguar Health verlängert Mandat für ATM-Programm mit Lucid Kapitalmärkte bis Ende 202515
JAGUAR HEALTH Aktie jetzt für 0€ handeln
14.08.Jaguar Health, Inc. - 8-K, Current Report2
14.08.Jaguar Health GAAP EPS of -$10.25, revenue of $2.98M10
14.08.Jaguar Health, Inc.: Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue302The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately 35% versus net Q1 2025 revenue of approximately...
► Artikel lesen
14.08.Jaguar Health, Inc. - 10-Q, Quarterly Report9
13.08.Earnings Preview For Jaguar Health3
12.08.Jaguar Health, Inc.: Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates161Click here to registerCompany plans to file its Earnings Report on August 14, 2025 on Form 10-Q for the quarter ended June 30, 2025Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference...
► Artikel lesen
10.07.Jaguar Health, Inc.: Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs414Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia®, conditionally approved for CID, to regulatory approval and commercialization...
► Artikel lesen
08.07.Jaguar Health, Inc.: Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health469Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications SAN FRANCISCO, CA / ACCESS Newswire / July 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ...
► Artikel lesen
30.06.Jaguar Health, Inc. - 8-K, Current Report1
30.06.Jaguar Health, Inc.: Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient259As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating...
► Artikel lesen
30.06.Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Buy374Original-Research: Jaguar Health Inc - from First Berlin Equity Research GmbH 30.06.2025 / 14:24 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group. The issuer...
► Artikel lesen
26.06.Jaguar Health, Inc.: Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset285Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value SAN FRANCISCO, CA / ACCESS Newswire / June 26, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"...
► Artikel lesen
25.06.Jaguar Health seeks EU approval for dog diarrhea treatment15
25.06.Jaguar Health, Inc.: Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs276Canalevia® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogsJaguar is exploring the possibility...
► Artikel lesen
Weiter >>
124 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1